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INTRODUCTION 
Breast cancer is the most common cause of cancer 
death in Malaysia [1]. About 20 to 30% of breast 
cancer patients have amplification of HER2 gene 
which confer them with more aggressive and poorer 
prognosis disease even when they received similar 
adjuvant treatment as their counterparts [2, 3].  
 Trastuzumab is a monoclonal antibody that 
blocks activation of HER2 receptors. There are seven 
major randomised trials on adjuvant trastuzumab in 
early HER2 breast cancer [4-9]. Three meta-analyses 
on these trials by different groups concur that adjuvant 
trastuzumab would be able to reduce recurrences and 
improve survival of HER2 breast cancer patients [10-
12]. However, two of the meta-analyses also found 
that trastuzumab increases risk for decline in heart 
function which could be as high as 2.45 folds [10, 11]. 
 This observation of improving survival but 
increase in cardiotoxicity with the use of adjuvant 
trastuzumab has also been reported in several 
retrospective studies worldwide [13-19]. To date, no 
study of such has been done in Malaysia where 
trastuzumab has been used in adjuvant setting since 
2006. 
 Therefore, the objective of this study is to 
analyse efficacy and toxicity of adjuvant trastuzumab 
in Malaysia by conducting the study in one of the main 
oncology tertiary centre in Malaysia. 
METHODS 
This is a two arm retrospective cohort study. The study 
cohort consisted of all non-metastatic HER2 positive 
breast cancer patients treated at University Malaya 
Medical Centre (UMMC) from October 2006 until 
May 2011. This starting date of our cohort was chosen 
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as October 2006 as this is when trastuzumab was first 
approved to be used for adjuvant breast cancer. 
Meanwhile the end date of our study cohort was May 
2011 to give at least 2 years of follow up data because 
the cut-off date for data analysis was May 2013. 
 Our patients’ HER2 status was determined 
using immunohistochemistry (IHC) as in-situ 
hybridization testing was only available in UMMC in 
September 2012. HER2 positivity was defined as 
tumour IHC staining score of 3+ as per ASCO/CAP 
guidelines [20]. 
 Two sources were used to identify patients for 
the study to ensure all eligible patients were captured. 
The first source was a prospectively maintained breast 
cancer database which was managed by UMMC 
surgical team. The second source was the oncology 
chemotherapy daycare appointment diaries to ensure 
that all patients who received adjuvant trastuzumab 
within the study timeframe were not missed out from 
the study. The two lists were compared and any 
overlap was noted. 
 After excluding those who were lost to follow 
up, a total of 170 patients fulfilled the inclusion criteria 
for the study (Table 1) and were included for the final 
analysis. Of these, 33 patients received adjuvant 
trastuzumab and the remaining 137 patients did not. 
Based on whether patients received adjuvant 
trastuzumab or not, we divided them into two cohort: 
‘trastuzumab’ and ’no trastuzumab’ cohort. As this is a 
retrospective study there was no control over the 
baseline characteristics or number of patients included 
in each arm and some imbalances were expected. 
These imbalances will be addressed statistically and 
will be discussed in subsequent part of the paper. 
 A data collection sheet was used to capture 
demographic, histopathological data, treatment 
received, site of first relapse, and date of relapse or 
death.  Disease free survival (DFS) is defined as time 
from diagnosis to recurrence of the cancer either 
locally, regionally or distantly. We defined overall 
survival (OS) as time from diagnosis to death from any 
cause.  
 For our first study objective of 
survival analysis, we identified two cohorts as 
explained above: ‘trastuzumab’ and ‘no trastuzumab’ 
cohort. Baseline characteristic between the two groups 
were compared using chi-squared test for categorical 
variables and independent t-test or Mann-Whitney test 
for continuous variables. DFS and OS were estimated 
for both groups using Kaplan-Meier method. 
Comparison of these outcomes between the two groups 
was based on a log rank test.  Cox proportional hazards 
regression models was used to analyse for potential 
covariates of age at diagnosis (39 years or younger, 40 
to 49 years, 50 to 59 years, or 60 years of age or 
older), nodal status (0, 1 to 3, 4 to 9, or 10 or more 
positive nodes), tumour stage as per standard 
international AJCC staging (T1, T2, T3 and T4), 
receptor status (ER positive vs ER negative) and grade 
of tumour (grade I vs grade II vs grade III). All 
statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS) version 21.0. 
Significance of all tests was taken as p < 0.05.  
Table 1 Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
Non metastatic breast cancer Metastatic disease 
HER2 positive HER2 negative 
 Recurrent breast cancer 
 Ductal carcinoma in situ 
 Trastuzumab used in 
neoadjuvant setting 
 Refuse clinically indicated 
other standard adjuvant 
treatment 
 Did not complete other 
standard adjuvant treatment 
 Lost to follow up 
 
 For the second study objective of trastuzumab 
toxicity, we divided the toxicity as either cardiac 
related or non-cardiac related. The toxicities were 
graded using the internationally accepted Common 
Terminology Criteria for Adverse Event (CTCAE) 
version 4.0. 
 Trastuzumab induced cardiotoxicity (TIC) was 
defined as either asymptomatic drop in left ventricular 
ejection function (LVEF), or symptomatic heart failure 
[21-27]. Asymptomatic drop in LVEF was defined as a 
decline in LVEF of at least 10% to below 55% without 
accompanying signs or symptoms [28]. 
 Patients’ LVEF were measured using 
echocardiography at baseline and at 3, 6, 9 and 12 
months whilst on treatment as a standard protocol at 
UMMC. Therefore to analyse for trastuzumab induced 
cardiotoxicity (TIC), we recorded the measured LVEF 
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as well as development of any clinical signs and 
symptoms of heart failure during the course of 
treatment.  
 We also recorded additional information to 
investigate potential risk factors for trastuzumab 
cardiotoxicity base on previous studies [21, 22, 25, 27, 
29, 30, 31,] which are age, low baseline LVEF, 
previous anthracycline exposure, hypertension, 
diabetes, hyperthyroidism, previous history of 
ischaemic heart disease and left sided radiotherapy. 
 Ethics committee of University Malaya 
approved the study on 28 March 2013 in accordance 
with good clinical practice guidelines. 
 
RESULTS 
Overall 
The study cohort consisted of 170 newly diagnosed 
non metastatic HER2 positive breast cancer patients. 
Median age was 53.4 ± 10.3 (range 31 - 81) years old. 
Of 170 patients in this study, 33 (19.4%) received 
adjuvant trastuzumab while 137 did not.  Despite this 
being a retrospective study with no control over who 
gets into one group over the other, surprisingly the 
demographic and clinicopathological features between 
the two groups were statistically balanced except for 
ER negativity which was higher in the trastuzumab 
group. 
 
Table 2 Clinical and pathological characteristic of patients 
according to subgroups 
Characteristics Trastuzumab 
[n (%)] 
No trastuzumab 
[n (%)]  
 
P-value 
Age at 
diagnosis 
(years) 
   Median (SD) 
 
 
 
51.4  
(SD±10.5) 
 
 
 
53.8 (SD±10.1) 
 
 
 
0.226(a) 
Age range 33-68 years 
old 
31 – 81 years old  
Age group 
   ≤ 39 
   40 – 49 
   50 – 59 
   ≥ 60 
 
5 (15.1) 
6 (18.2) 
13 (39.4) 
9 (27.3) 
 
14 (10.2) 
26 (19.0) 
57 (41.6) 
40 (29.2) 
 
0.884 
    
Race 
   Malay 
   Chinese 
   Indian 
   Others 
 
9 (27.3) 
19 (57.6) 
5 (15.1) 
0 (0) 
 
37 (27.0) 
73 (53.3) 
26 (19.0) 
1 (0.7) 
 
0.909 
    
Tumour size  
(T stage) 
T1 (< 2cm) 
T2 (2cm – 5cm) 
T3 (> 5cm) 
T4 (locally 
advanced) 
 
 
 
8 (24.2) 
22 (66.7) 
3 (9.1) 
0 (0) 
 
 
43 (31.4) 
78 (56.9) 
14 (10.2) 
2 (1.5) 
 
 
0.706 
Tumour size 
Mean (cm) ±SD 
 
3.5 ± 2.6 
 
3.8 ± 3.1 
 
0.542 (a) 
    
Tumour grade 
   1 
   2 
   3 
   Unknown 
 
0 (0) 
16 (48.5) 
17 (51.5) 
0 (0) 
 
5 (3.6) 
61 (44.5) 
65 (47.4) 
6 (4.4) 
 
0.418 
    
Lymph node 
status 
   0 
   1-3 
   4-9 
   >9 
 
 
13 (39.3) 
14 (42.4) 
4 (12.1) 
2 (6.1) 
 
 
78 (56.9) 
27 (19.7) 
18 (13.1) 
14 (10.2) 
 
 
0.052 
    
Estrogen 
receptor (ER) 
   Positive 
   Negative 
 
 
8 (24.2) 
25 (75.8) 
 
 
64 (46.7) 
73 (53.3) 
 
 
0.019 
(a) Independent t-test; All other variables were analysed using chi-
squared or fisher-exact test; SD = standard deviation  
 
Disease Free Survival (DFS) 
At time of analysis in May 2013, 44 out of 170 
patients in the cohort (25.9%) developed recurrences. 
 Of the 44 patients who recurred at time of 
analysis, 41 occurred in patients who did not receive 
adjuvant trastuzumab. Meanwhile only three patients 
who did receive adjuvant trastuzumab, developed 
breast cancer recurrence. This resulted in a significant 
different of DFS between the two groups [(90.9% in 
trastuzumab group vs 74.5% in ‘no trastuzumab’ group 
(p = 0.027)] (Figure 1). 
 Univariate and multivariate analysis showed 
that DFS of our patients are affected by tumour size, 
number of nodal involvement and whether or not they 
received adjuvant trastuzumab. 
 The number of event in trastuzumab cohort is 
too small for robust statistical analysis but it can be 
seen that all patients regardless of age at diagnosis, 
tumour size, estrogen receptor status and tumour grade 
would significantly benefit from adjuvant trastuzumab 
in improving their DFS (Table 3). The magnitude of 
difference in DFS from adjuvant trastuzumab is largest 
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in those younger than 39 years old whereby all five 
patients who received adjuvant trastuzumab were free 
of disease (100%) compared to only 50% of those in 
the same age group who did not get adjuvant 
trastuzumab (Table 3 and Figure 2). 
 
Figure 1 Kaplan Meier curve: Disease free survival (DFS) 
between trastuzumab and ‘no trastuzumab’ group  
 
Table 3 Analysis of DFS between trastuzumab and non 
trastuzumab group 
Number of Events (%) 
Factor Trastuzumab 
(n = 33) 
No 
trastuzumab 
(n = 137) 
P-value 
(Stratified 
Logrank) 
Age group 
<39 years old 
40 – 49 
50 – 59 
>60 years old 
 
0/5 (0) 
1/6 (16.7) 
2/13 (15.4) 
0/9 (0) 
 
7/14 (50.0) 
7/26 (26.9) 
18/57 (31.6) 
9/49 (18.4) 
 
0.025 
    
Tumour stage 
T1 
T2 
T3 
*T4 
 
 
1/8 (12.5) 
1/22 (4.5) 
1/3 (33.3) 
- 
 
 
7/43 (16.3) 
28/78 (35.9) 
4/14 (28.5) 
2/2 (100) 
 
 
0.022 
    
N stage 
N0 
N1 
N2 
N3 
 
0/14 (0) 
0/13 (0) 
1/4 (25.0) 
2/2 (100) 
 
18/81 (22.2) 
7/24 (29.2) 
7/18 (38.9) 
9/14 (64.3) 
 
0.066 
    
Estrogen 
receptor (ER) 
ER positive 
ER negative 
 
 
 
1/8 (12.5) 
2/25 (8.0) 
 
 
 
18/64 (28.1) 
23/73 (31.5) 
 
 
 
0.021 
    
Grade 
*I 
II 
III 
 
- 
2/16 (12.50 
1/17 (5.9) 
 
3/5 (60.0) 
14/59 (23.7) 
20/63 (31.7) 
 
0.033 
 
 
 
*There were no grade I and T4 patient in trastuzumab group 
 
 
Figure 2 Kaplan Meier curve of DFS difference between 
trastuzumab and non trastuzumab cohort in those aged 39 years old 
or younger  
 
Overall Survival 
Four-years OS in trastuzumab group was 91% 
compared to 84.7% in non-trastuzumab group and was 
non-statistically significant (p=0.30) although the two 
graphs are separating widely at the end of the analysis 
(Figure 3). 
 
 
Figure 3 Kaplan Meier curve of overall survival between 
trastuzumab and non-trastuzumab cohort 
 
Trastuzumab Treatment Experienced 
At the time that this study was carried out, there was 
no accepted guideline on how trastuzumab should 
ideally be given. Therefore, among our study cohort, 
out of 33 patients who received adjuvant trastuzumab, 
24 patients (72.7%) received trastuzumab following 
the last cycle of chemotherapy, every three weeks for 
17 times as per HERA trial protocol [5]. Four patients 
(12.1%) while also receiving 17 times of three weekly 
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trastuzumab, started having the treatment concurrently 
with adjuvant chemotherapy.  Another four patients 
(12.1%) received adjuvant trastuzumab weekly for 
nine times concurrently with either vinorelbine or 
docetaxel as per FinHER protocol [7]. Meanwhile one 
patient received adjuvant trastuzumab together with 
docetaxel and carboplatin (TCH regime) as per BCIRG 
trial protocol [6]. After an update of the FinHER 
protocol in 2009 showing no significant benefit of both 
DFS and OS [25], no more patients at the centre 
received trastuzumab following the FinHER protocol. 
 
 
Figure 4 Trastuzumab side effects 
 
Most patients (69.7%) tolerated trastuzumab 
with no side effects (Figure 4).  Five patients (15.2%) 
had trastuzumab induced cardiotoxicity and they are 
all of grade I toxicity. No patients suffer higher grade 
II, III or IV cardiotoxicity.  Of the five patients who 
experienced cardiotoxicity, only one patient had a drop 
of LVEF to less than 50% resulting in permanent 
discontinuation of trastuzumab. The other four patients 
had recovery of their LVEF after momentarily 
withholding treatment and subsequently were able to 
complete the planned course of adjuvant trastuzumab. 
No obvious risk factor for developing trastuzumab 
associated cardiotoxicity could be identified (Table 4). 
  
DISCUSSION 
The DFS rate at four year of 90.9% in this study is 
similar to that reported in adjuvant trials [5, 26, 32]. 
Adjuvant trastuzumab benefited our patients regardless 
of age group, tumour size, tumour stage, ER status and 
tumour grade.  
 Interestingly we found that oncologists at our 
centre tend to offer adjuvant trastuzumab to ER 
negative patients rather than those with ER positive 
disease. This may be because it is known that ER 
negativity equates to poorer prognosis [33, 34] 
compared to ER positive disease whereby prolong 
hormonal therapy can be offered. 
 
Table 4 Risk factors for cardiotoxicity 
 Cardiac 
toxicity 
(n = 5) 
No cardiac 
toxicity 
(n = 28) 
P value 
    
Age (mean) 57.6 +-8.4 
years old 
 
50.3 +-10.6 
years old 
0.158 (a) 
Baseline LVEF 
Mean ± SD 
67.8% ±7.9 69.4% ± 6.2 0.612 (a) 
    
Anthracycline 
exposure 
Yes 
No 
 
 
5 (100%) 
0 (0%) 
 
 
25 (75.8%) 
3 (9.1%) 
 
 
1.00 
    
Hypertension 
Yes 
No 
 
1 (20%) 
4 (80%) 
 
4 (12.1%) 
24 (72.7%) 
 
1.00 
Diabetes 
Yes 
No 
 
0 (0%) 
5 (100%) 
 
1 (3.0%) 
27 (81.8%) 
 
1.00 
    
Hyperthyroidism 
Yes 
No 
 
0 (0%) 
5 (100%) 
 
1 (3.0%) 
27 (81.8%) 
 
1.00 
    
IHD 
Yes 
No 
 
0 (0%) 
5 (100%) 
 
1 (3.0%) 
27 (81.8%) 
 
1.00 
    
Left sided 
radiotherapy 
Yes 
No 
 
 
4 (80%) 
1 (20%) 
 
 
9 (27.3%) 
19 (57.6%) 
 
 
0.06 
(a) Independent t-test; other categorical variables were analysed 
using Fisher-Exact test as does not fulfill requirement for Chi-
squared test 
 
Overall Survival 
Adjuvant trastuzumab does not seem to have 
significant impact on overall survival of our patients 
although it was seen that the Kaplan-Meir curves for 
OS between the two groups were starting to separate at 
the end of the study period. It could be hypothesized 
that with larger sample size and longer follow up, the 
difference could become significant. 
 
Trastuzumab Induced Cardiotoxicity (TIC) 
When compared to major landmark trials, the 
incidence of trastuzumab induced asymptomatic drop 
in LVEF in our study of 15.2% is comparable to 
Adjuvant Transtuzumab Efficacy and Toxicity in Breast Cancer 
 
 
Vol 3 (1) (2018) 33-42 | jchs-medicine.uitm.edu.my | eISSN 0127-984X 
 
38 
18.9% reported in BCIRG trial [6] but higher 
compared to 7% reported in HERA trial [26]. 
 What appear to be almost double increase in 
cardiotoxicity in our study population compared to 
HERA trial may well be related to the difference in the 
definition of trastuzumab induced cardiotoxicity (TIC) 
used. In fact, if the definition used in HERA trial is 
adapted to our study, only one of our patients has a 
drop of LVEF to less than 50% resulting in 3% 
trastuzumab related cardiac event, which would be 
comparable to that of 7% in HERA trial [26]. 
 As for grade III/IV trastuzumab related 
cardiotoxicity, it is reassuring that none of our patients 
develop grade III/ IV cardiotoxicity compared to 4.5% 
incidence across the five major RCTs [10].  
 Meanwhile, comparing our result with other 
retrospective studies, our cardiotoxicity rate of 15.2% 
was much lower compared to most studies found. For 
example the rate of cardiotoxicity was 28.2% among 
Japanese patients [19] and 38% among Moroccan 
patients [29]. The Japanese study had more elderly 
patients which may explain the higher incidence of 
cardiotoxicity as age itself increases cardiac risk [19]. 
On the other hand the Moroccan study did not specify 
why their cardiotoxicity rate was higher than that of 
RCTs [29]. 
 Analyzing potential risk factors for 
trastuzumab induced cardiotoxicity (TIC), those 
having left sided breast/chest wall radiotherapy tend to 
show a higher risk of getting TIC. Interestingly having 
previous history of ischaemic heart disease does not 
predispose one to TIC. However this results need to be 
interpreted with caution due to small number of event 
observed in trastuzumab group of our study (five 
events). 
 Even though several meta-analysis of major 
adjuvant trials have shown highly significant benefit of 
adjuvant trastuzumab in HER2 overexpressed breast 
cancer, trials were done under controlled environment 
on selected patients’ population which can be quite 
different to what actually happen in real practice 
especially in countries with limited resources and 
different culture and belief, like Malaysia, whereby 
clinical practice sometimes cannot follow international 
guidelines or that as outlined in trials’ protocol. 
Furthermore even though more than 13000 patients 
were included in all five major randomised trials, only 
HERA trial included Asian patients [5].  
 Therefore, our observational retrospective 
study provides results that directly reflect practice at 
our centre and are directly applicable to our study 
population. Furthermore while there may be many 
retrospective studies already done on the issue of 
safety and efficacy of adjuvant trastuzumab in breast 
cancer, most of them were of single arm study. Our 
study on the other hand has patients from the same 
population as the comparison arm. Not only do our 
patients have similar demographic features, but as they 
come from the same cancer centre, they would tend to 
have less different variation in other aspects of breast 
cancer treatment thus producing a more equal group 
for results comparison.  
 As with other retrospective studies, missing 
data was a limitation. The missing data were from 
missing folders and untraceable patients despite 
attempts to trace them. These patients were excluded 
from final analysis although none were from the 
trastuzumab group. 
 The low rate of prescription for adjuvant 
trastuzumab at our centre resulted in a small sample 
size for the trastuzumab group despite the cohort 
spanning over five years. This small sample size was a 
major limitation for more robust statistical analysis. 
 It is suggested that the study be repeated in the 
future as it is expected that the number of patients 
receiving adjuvant trastuzumab will be increased at our 
centre. Collaboration with other major oncology 
tertiary centres also would lead to bigger sample size 
and a more representative study population. 
 
CONCLUSION 
Our study is the first in Malaysia to document a 
significant effect of adjuvant trastuzumab in improving 
DFS. Our results also show a trend towards better OS 
in our HER2 amplified breast cancer patients who 
were treated with adjuvant trastuzumab compared to 
those who did not receive the drug.  
 We also found that treatment was well 
tolerated. The only one case of permanent 
discontinuation of trastuzumab due to treatment related 
cardiotoxicity highlighted the importance of 
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appropriate patient selection for treatment and careful 
cardiac monitoring of patients who were on treatment. 
 Therefore, our study concluded that adjuvant 
trastuzumab should be considered in HER2 amplified 
breast cancer patients as the risk of trastuzumab 
induced cardiotoxicity can be justified, given the 
significant absolute improvement in DFS by 16%.  
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